肿瘤导向治疗是将化疗药物结合到靶向载体上,使之伴随载体一起进入肿瘤组织,以增强对肿瘤细胞的选择性杀伤作用,并减低对正常细胞的毒性影响。自1975年Kohler和Milstein创立杂交瘤技术以来,人们即考虑用单克隆抗体作为载体来提高药物对肿瘤的针对性[1、2]。其机制是先制备出针 Tumor-directed therapy involves the incorporation of chemotherapeutic agents on targeting vectors that, in conjunction with carriers, enter tumor tissue to enhance selective killing of tumor cells and reduce the toxic effects on normal cells. Since the hybridoma technology was established in 1975 by Kohler and Milstein, people are considering using monoclonal antibodies as carriers to enhance the targeting of drugs to tumors [1, 2]. The mechanism is to prepare the needle